Zogenix Soars 10% Today Despite Diluting Investors

Zogenix Soars 10% Today Despite Diluting Investors

Pixabay / Goumbik / CC0 Creative Commons

What happened
After the company announced it will tap investors for money to fuel R&D (research and development) and pre-commercialization efforts for its Dravet syndrome drug, shares in Zogenix (NASDAQ: ZGNX) are rallying 10% at 2 p.m. EDT today.

So what
Zogenix rolled out impressive phase 3 study data last week, showing its ZX008 can significantly reduce the number of monthly seizures in people diagnosed with Dravet syndrome, a rare form of child-onset epilepsy.

View Original Article Here

Repost is the designation for articles collected from the Internet whose content may interest our readers. These articles are not written by our staff and they do not necessarily reflect our views.

Related posts